Mobile menu

Alba Therapeutics in Washington Post

August 18, 2008

Alba Therapeutics in Washington Post


A new research study presented at the Digestive Disease Week meeting in San Diego found that a medicine called AT-1001 may protect celiac disease patients from exposure to gluten by preventing gluten from crossing the intestinal mucosa.


A new research study presented at the Digestive Disease Week meeting in San Diego found that a medicine called AT-1001 may protect celiac disease patients from exposure to gluten by preventing gluten from crossing the intestinal mucosa. In a second study at the meeting, researchers concluded that the current criteria for diagnosing celiac is too stringent, resulting in many patients going undiagnosed and untreated.

www.washingtonpost.com/wp-dyn/content/article/2008/05/19/AR2008051901173.html

Think you may have celiac disease?

Symptoms Checklist
OUR PARTNERS